

Paradigm Biopharmaceuticals Ltd

19:07 21 Nov 2018

Paradigm Biopharmaceuticals signs agreement for use of iPPS in treatment of MPS

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has executed an agreement with a US-based medical school for use of its injectable Pentosan Polysulfate Sodium (iPPS) in the treatment of mucopolysaccharidoses (MPS).

The exclusive in-licence agreement has been signed with the Icahn School of Medicine at Mount Sinai, New York, and covers use of iPPS for MPS, a group of inherited lysosomal storage disorders.

MPS is a rare inherited disease which causes debilitating joint pain and dysfunction and a key unmet medical need in this class of inherited disease is the lack of treatment.

READ: Paradigm Biopharmaceuticals enters agreement to treat US-based sportspeople

The agreement includes Phase 2a safety and efficacy data which provides valuable long-term safety data on iPPS, which can be included in US FDA submissions for Paradigm's OA/BMEL primary indication.

Synergies with OA/BMEL program

Paradigm said the licensing agreement and accompanying data was complementary and synergistic to the company's OA/BMEL program.

As such, the company said it was a logical and valuable addition to the product pipeline and IP portfolio at this time.

READ: Paradigm Biopharmaceuticals boosts financial position with \$2.32 million R&D tax rebate

The agreement was executed on attractive commercial terms, providing the company with highly valuable intellectual property (IP).

Based on Paradigm's review of the human clinical data, the product development for the targeted population of people who have inherited the rare disease could receive 'fast-track' approval following a pivotal Phase 2b clinical trial.

The new IP will fall under the same terms of exclusivity and supply that Paradigm enjoys with bene pharmaChem.


READ: Paradigm Biopharmaceuticals secures \$9 million to accelerate phase III

This newly in-licensed indication is fully funded for the next 12 months and beyond.

Price: \$2.60

Market Cap: \$500.19 m

1 Year Share Price Graph



September 2018 March 2019 September 2019

Share Information

Code: PAR

Listing: ASX

52 week High Low
2.62 0.693392

Sector: Pharma & Biotech

Website: www.paradigmbiopharma.com

Company Synopsis:

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

Paradigm's primary focus remains reading-out of the Phase 2b OA/BMEL clinical trial head-line results, and this is expected in mid to late December 2018.

Leader in medical research

The Icahn School of Medicine at Mount Sinai is a not-for-profit corporation, which is a leader in medical and scientific training and education, biomedical research and patient care.

Mount Sinai Health System is New York City's largest integrated health delivery system encompassing seven hospital campuses, leading medical school, and vast network of ambulatory practices throughout the greater New York region.

Paradigm is focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA approved drug that has a long track record of safely treating inflammation.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount of up to Twenty Five Thousand dollars (\$25,000).